FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Oxlumo works by degrading HAO1 messenger RNA and reducing the synthesis of GO, which inhibits hepatic production of oxalate – the toxic metabolite responsible for the clinical manifestations of PH1. Visit OXLUMO.com for more information, including full Prescribing Information.
52 
Let's personalize your content